Investors looking for a source of stable dividends should consider preferred shares, says John Heinzl, of the Globe and Mail. He dissects the pros and cons of them as a whole, and offers a few possibilities for you to consider.
What do you think of preferred shares? Is this a good time to buy them?
Preferred shares stake out the middle ground in a company's capital structure, ranking ahead of common shares but behind bonds. This has advantages and disadvantages for the investor.
On the plus side, if a company needs cash, it will cut common dividends before it touches preferred dividends. If the company goes bust, preferred shareholders are second in line to bondholders for any assets of the business.
Another advantage of preferred shares is that their dividends qualify for the dividend tax credit, making them suitable for taxable accounts. And because preferreds generally pay a fixed dividend, they are less volatile than common shares.
Top 5 Financial Companies For 2015: Sun Life Financial Inc.(SLF)
Sun Life Financial Inc., together with its subsidiaries, provides various life and health insurance, savings, investment management, retirement, and pension products and services to individuals and corporate customers. It offers individual life insurance policies, including individual term life, universal life, critical illness, disability, accident, and accidental death and dismemberment insurance policies; and group life insurance policies. The company also provides individual health insurance, long-term care insurance, group health benefits, dental benefits, and group insurance; and various individual and group annuity, retirement, and investment income products and services, such as mutual and pooled funds, variable and fixed annuities, savings, retirement and pension plans, and education savings. In addition, it offers asset management services for corporate retirement plans, separate accounts, public or government funds, and insurance company assets to institutional clients; and advisory services to individual investors. Further, the company provides run-off reinsurance services. Sun Life Financial Inc. distributes its products through direct sales agents, independent and managing general agents, financial intermediaries, broker-dealers, banks, pension and benefit consultants, and other third-party marketing organizations. The company operates primarily in Bermuda, Canada, China, Hong Kong, India, Indonesia, Ireland, the Philippines, the United States, and the United Kingdom. Sun Life Financial Inc. was founded in 1999 and is based in Toronto, Canada.
Advisors' Opinion:- [By Tim Brugger]
Initially, the deal Sun Life Financial (NYSE: SLF ) struck in December to sell its U.S. annuity portfolio and some life insurance products for $1.35 billion to Delaware Life Holdings, a Guggenheim Partners-owned company, was scheduled to be completed by Q2 of 2013.
- [By Amanda Alix]
Insurance companies have created an entire industry based upon risk, and except for AIG (NYSE: AIG ) during the financial crisis, it has worked out pretty well. So, it's not a stretch to imagine a large life insurer like Canada's Sun Life Financial (NYSE: SLF ) assuming the pension liability for the Canadian Wheat Board's defined benefit plan in a recent $147 million deal, the first such accord in Canada's history.
- [By Patricio Kehoe] sport a 200% ratio. Moreover, the company�� excessive capital should allow it to maintain the above average dividend yield of 2.66% offered to shareholders.
Valuation
Over the next five years growth in the Asian market will likely boost the overall modest premium growth rate, averaging it at 2%, while the total revenue CAGR recovers to 3% after the steep declines reported since 2012. Furthermore, Manulife�� ROE will continue its current upward trend, increasing from 2013�� 10.9% to an average 12% by 2018, accompanied by the steadily expanding net margins of 16.8%. While it will take some time for the company�� growth to accelerate, I feel bullish about management�� optimism regarding its business shift, and see the dividend yield and returns on equity as solid benefits for a long term investment. Moreover, the firm is currently trading at a 10% price discount relative to the industry average of 14.0x, making it a relatively inexpensive buy.
Disclosure: Patricio Kehoe holds no position in any stocks mentioned.
Also check out: George Soros Undervalued Stocks George Soros Top Growth Companies George Soros High Yield stocks, and Stocks that George Soros keeps buyingAbout the author:Patricio KehoeA fundamental analyst at Lone Tree Analytics Currently 5.00/512345Rating: 5.0/5 (1 vote)
Voters: Subscribe via Email Subscribe RSS Comments Please leave your comment: $(document).ready(function(){$('#body_login, #watch, #follow, #fake_submit').click(function(){$.colorbox({innerWidth:"600px",innerHeight:"400px",iframe:false,href:"http://www.gurufocus.com/modules/login_register.php"});});});
More GuruFocus Links Latest Guru Picks Value Strategies Warren Buffett Portfolio Ben Graham Net-Net Real Time Picks Buffett-Munger Screener Aggregated Portfolio Undervalued Predictable ETFs, Options Low P/S Companies Insider Trends 10-Year Financials 52-Week Lows Interactive Charts Model Portfolios DCF Calculato - [By Monica Gerson]
Sun Life Financial (NYSE: SLF) shares gained 2.47% to create a new 52-week high of $34.80 on Q3 results. Sun Life reported its Q3 operating net income from continuing operations of $422 million.
Top 5 Investments For 2014: Regeneron Pharmaceuticals Inc.(REGN)
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.
Advisors' Opinion:- [By John Divine]
Regeneron Pharmaceuticals (NASDAQ: REGN ) , which was one of yesterday's 3 Best Stocks, slipped 4.7%, giving up all of Tuesday's gains and a little bit more. Today's slip may just be a reflection of investors' taking their gains from yesterday's surge, but it could also signal the exit of some longer-term investors spooked by the Fed's comments today. Though it's often not a good idea, people often sell off the winners in their portfolio first, holding on to the losers in hopes for a comeback. And most longer-term investors in Regeneron are winners -- the stock's up nearly 850% in the past three years alone.�
Top 5 Investments For 2014: Endologix Inc(ELGX)
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. It offers the ELG System, a stent graft and delivery system for the treatment of abdominal aortic aneurysms through minimally-invasive endovascular repair. The company also provides aortic extensions and limb extensions, which attach to the main body of ELG Device, enabling physicians to customize it to fit the patient?s anatomy. In addition, it offers accessories, such as guidewires, snares, and catheter introducer sheaths that facilitate the optimal delivery of its ELG Device. Endologix, Inc. sells its products through direct sales force and independent distributors in the United States, Europe, Asia, South America, and Mexico. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Endologix (NASDAQ: ELGX) were down 23.48 percent to $13.68 on lowered guidance, analyst downgrades. Oppenheimer downgraded the stock from Outperform to Market Perform and cut the price target from $20.00 to $16.00.
Top 5 Investments For 2014: Methanex Corporation (MEOH)
Methanex Corporation, together with its subsidiaries, engages in the production, marketing, and sale of methanol. The company also purchases and re-sells methanol produced by others. Its methanol is a clear liquid commodity chemical that is used to produce traditional chemical derivatives, including formaldehyde, acetic acid, and various other chemicals. The company�s methanol is also used in energy-related applications; for blending into gasoline, as a feedstock in the production of dimethyl ether, which can be blended with liquefied petroleum gas for use in household cooking and heating, and in the production of biodiesel; and used to produce methyl tertiary-butyl ether, a gasoline component, as well as used into olefins applications. The company supplies its methanol to petrochemical producers and distributors in North America, the Asia Pacific, Europe, and Latin America. Methanex Corporation was founded in 1968 and is headquartered in Vancouver, Canada.
Advisors' Opinion:- [By Aimee Duffy]
The North American natural gas revolution has had an undeniable effect on domestic energy companies. While many of the companies we read about every day are more or less obvious investment ideas, be they oil and gas producers or pipeline operators, there are still a few opportunities floating under the radar. In this video, Fool.com contributor Aimee Duffy takes a look at Canada's Methanex (NASDAQ: MEOH ) , an energy company that thrives on cheap natural gas, and as a result is striking deals left and right.
No comments:
Post a Comment